Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2002-07-26
2010-10-12
Parkin, Jeffrey S (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S186100, C424S187100, C424S188100, C424S192100, C424S193100, C424S194100, C424S196110
Reexamination Certificate
active
07811573
ABSTRACT:
The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selectively deliver these antigen(s) as well as active compounds to dendritic cells, endothelial cells and macrophages, due to its capability of targeting these A PC and of activating their maturation and functions and of increasing Th-1 type immune responses as an adjuvant. Therefore, due to these characteristics and to the distribution of these cells in the body (during physiological and pathological disorders), biologically active Tat, fragments or derivates thereof containing the RGD region, can be used for preventive, therapeutic and/or diagnostic purposes for HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumors.
REFERENCES:
patent: 2005/0063978 (2005-03-01), Fritz et al.
patent: 2 426 490 (2002-04-01), None
patent: WO 99/27958 (1999-06-01), None
patent: WO 00/78969 (2000-12-01), None
patent: WO 01/00232 (2001-01-01), None
patent: WO 01/12220 (2001-02-01), None
patent: WO 01/19393 (2001-03-01), None
patent: WO 01/54717 (2001-08-01), None
patent: WO 01/54719 (2001-08-01), None
patent: WO 01/91536 (2001-12-01), None
patent: WO 02/32451 (2002-04-01), None
Salfeld et al. A tripartite HIV-1 tat-env-rev fusion protein. The EMBO journal 1990, vol. 9, No. 3, pp. 965-970.
Schiller et al. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opinion on Biological Therapy Jul. 2001, vol. 1, No. 4, pp. 571-581.
Gerotto et al. Effect of Retreatment with Interferon Alone or Interferon plus Ribavirin on Hepatitis C Virus Quasispecies Diversification in Nonresponder Patients with Chronic Hepatitis C. Journal of Virology, Sep. 1999, vol. 73, No. 9, p. 7241-7247.
Huang et al. Recent development of therapeutics for chronic HCV infection. Antiviral Research 2006, vol. 71, p. 351-362.
Navas-Martin et al. Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. Journal of Neurology 2004, vol. 10, p. 75-85.
Tonini et al. Current approaches to developing a preventative HIV vaccine. Current Opinion in Investigational Drugs 2005, vol. 6, No. 2, pl. 155-162.
Yin et al. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Cellular and Molecular Life Sciences 2006, vol. 63, p. 1706-1724.
Addo M.M. et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A. Feb. 13, 2001;98(4):1781-6.
Barillari G. et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood. Jul. 15, 1999;94(2):663-72.
Fanales-Belasio E. et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol. Jan. 1, 2002;168(1):197-206.
Kim D.T. et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. Aug. 15, 1997;159(4):1666-8.
Albini, A. et al., “Angiogenic properties of human immunodeficiency virus type 1 Tat protein”, Proc. Natl. Acad. Sci. USA 92:4838-4842 (1995).
Albini, A. et al., “The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells”, Nature Med. 2:1371-1375 (1996).
Albini, A. et al., “HIV-1 Tat protein mimicry of chemokines”, Proc. Natl. Acad. Sci. USA 95:13153-13158 (1998).
Albini, A. et al., “Identification of a novel domain of HIV tat involved in monocyte chemotaxis”, J. Biol. Chem. 273:15895-15900 (1998).
Allen, T. et al., “Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia”, Nature 407:386-390 (2000).
Badou, A. et al., “Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway”, J. Virol. 74:10551-10562 (2000).
Barillari, G. et al., “Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis”, J. Immunol. 149:3727-3734 (1992).
Barillari, G. et al., “The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence”, Proc. Natl. Acad. Sci USA 90:7941-7945 (1993).
Barillari, G. et al., “Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin”, J. Immunol. 163:1929-1935(1999).
Benelli, R. et al., “Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides”, AIDS 12:261-268 (1998).
Benjouad, A. et al., “Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus (HIV-1)”, FEBS Lett. 319:119-124 (1993).
Boykins, R. et al., “Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis”, J. Immunol. 163:15-20 (1999).
Cafaro, A. et al, “Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine”, Nature Med. 5:643-650 (1999).
Cafaro, A. et al., “SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine”, J. Med. Primatol. 29:193-208 (2000).
Cafaro , A. et al., “Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)”, Vaccine 19:2862-2877 (2001).
Chang, H. C. et al., “HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region”, AIDS 11:1421-1431 (1997).
Chang H.-K. et al., “Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein”, J. Biomed. Sci. 2:189-202 (1995).
Chirmule, N. et al., “Human immunodeficiency virus Tat induces functional unresponsiveness in T cells”, J. Virol. 69:492-498 (1995).
Cohen, S. et al., “Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge”, Proc. Natl. Acad. Sci. USA 96:10842-10847 (1999).
Derossi, D. et al., “Trojan peptides: the penetratin system for intracellular delivery”, Trends Cell. Biol. 8:84-87 (1998).
Ensoli, B. et al., “Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients”, Nature 345:84-86 (1990).
Ensoli, B. et al., “Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation”, J. Virol. 67:277-287 (1993).
Ensoli, B. et al., “Synergy between basic fibroblast growth factor and HIV-1
Humphrey Louise
Istituto Superiore di Sanita
Jones Day
Parkin Jeffrey S
LandOfFree
Compositions of antigens bound to HIV-1 Tat, fragments or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of antigens bound to HIV-1 Tat, fragments or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of antigens bound to HIV-1 Tat, fragments or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4188501